Bengt I. Eriksson

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

Bengt I. Eriksson, Lars C. Borris, Richard J. Friedman et al. · New England Journal of Medicine · 2008 · 1.4K citations · Full text

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial

Bengt I. Eriksson, Ola E. Dahl, Nadia Rosencher et al. · The Lancet · 2007 · 1.1K citations

Thrombosis, Venous Disease, Venous Thrombosis +13

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

Ajay K. Kakkar, Benjamin Brenner, Ola E. Dahl et al. · The Lancet · 2008 · 1.1K citations

Total Hip Arthroplasty, Thrombosis, Venous Thrombosis +8

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

Bengt I. Eriksson, O.E. Dahl, Nadia Rosencher et al. · Journal of Thrombosis and Haemostasis · 2007 · 983 citations · Full text

Total Knee Replacement, Thrombosis, Venous Disease +8

Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery

Kenneth A. Bauer, Bengt I. Eriksson, Michael R. Lassen et al. · New England Journal of Medicine · 2001 · 633 citations · Full text